Medication info
Telmisartan/Amlodipine/Atorvastatin Tablets 80/10/20 mg

Telmisartan/Amlodipine/Atorvastatin Tablets 80/10/20 mg

Prescription medicationTabletOral
Ingredient · strength
Telmisartan›80mg / 1 tabletAmlodipine Besylate›13.87mg / 1 tabletRosuvastatin Calcium Micronized›20.8mg / 1 tablet
Manufacturer / importer
Jeil Pharmaceutical Co., Ltd.
Appearance
An oval bilayer tablet consisting of a white layer and a light blue layer
Packaging
30 tablets (10 tablets/PTP x 3)
Approval status
Active

MFDS item code 201801982 · Approved 2018.05.10 · Insurance code 645405330

Summary

Main use
Treatment of hypertension and dyslipidemia, and inhibition of atherosclerosis progression and cardiovascular risk
Who takes it
Adults
Adult dose
Take 1 tablet once daily with water, regardless of meals. If possible, it is recommended to take it at the same time each day (e.g., in the morning). This medication is for adults only. The dose should be individualized for each patient based on the efficacy and tolerability of the telmisartan/amlodipine combination and rosuvastatin. For patients taking the telmisartan/amlodipine combination together with rosuvastatin alone, they may switch to this medication (a combination product containing the same amount of each active ingredient) for convenience. ○ Telmisartan/amlodipine combination Before administering the telmisartan/amlodipine combination, it is recommended that the dose be adjusted using the individual components (amlodipine or telmisartan). However, if blood pressure is not controlled with the individual components, switching directly to the telmisartan/amlodipine combination may be considered as follows. - 40/5 mg: For patients whose blood pressure is not adequately controlled with amlodipine 5 mg or telmisartan 40 mg. - 80/5 mg: For patients whose blood pressure is not adequately controlled with amlodipine 5 mg or this medication 40/5 mg. - 40/10 mg: For patients whose blood pressure is not adequately controlled with amlodipine 10 mg. - 80/10 mg: For patients whose blood pressure is not adequately controlled with amlodipine 10 mg or this medication 40/10 mg. ◦ Patients with renal impairment: No dose adjustment is necessary in patients with mild or moderate renal impairment. However, in patients with severe renal impairment, it is recommended to start treatment at a low dose and increase the dose gradually. Periodic monitoring of serum potassium and creatinine levels is also recommended. ◦ Patients with hepatic impairment: The daily dose of telmisartan should not exceed 40 mg in patients with mild or moderate hepatic impairment. ◦ Elderly patients: In elderly patients aged 75 years or older, treatment should be started at a low dose and the dose increased gradually because amlodipine clearance is reduced. ○ Rosuvastatin 1. Primary hypercholesterolemia (type IIa, including heterozygous familial hypercholesterolemia), mixed dyslipidemia (type IIb), primary dysbetalipoproteinemia (type III), and homozygous familial hypercholesterolemia Patients should follow a standard cholesterol-lowering diet before and during treatment with rosuvastatin and continue it throughout the treatment period. Rosuvastatin may be taken at any time of day, regardless of meals. The initial dose is 5 mg once daily. If a greater reduction in LDL cholesterol is needed, the dose may be adjusted to a maintenance dose. The maintenance dose is 10 mg once daily, which controls the condition in most patients. The maintenance dose should be adjusted as appropriate according to LDL cholesterol levels, treatment goals, and the patient's response, at intervals of 4 weeks or longer; the dose may be increased to a maximum of 20 mg once daily. 2. Elderly patients: No dose adjustment is necessary. 3. Patients with renal impairment: No dose adjustment is necessary in patients with mild or moderate renal impairment. Do not administer to patients with severe renal impairment. Particular caution should be exercised when administering rosuvastatin 20mg to patients with moderate renal impairment. 4. Patients with hepatic impairment: No increase in systemic exposure to rosuvastatin was observed in patients with a Child-Pugh score of 7 or less, but an increase was observed in patients with a Child-Pugh score of 8 or 9. Renal function testing should be considered in these patients. There is no experience with administration in patients with a Child-Pugh score greater than 9. Do not administer rosuvastatin to patients with active liver disease. 5. Race: Because systemic exposure to rosuvastatin is increased in Asian patients, the recommended initial dose is 5 mg. Administration of the 40 mg dose is contraindicated. 6. Patients predisposed to myopathy: The recommended initial dose for patients predisposed to myopathy is 5 mg. Administration of the 40 mg dose of rosuvastatin is contraindicated in some of these patients. In a drug interaction study of the active ingredients of this medication, telmisartan/amlodipine 80/10mg and rosuvastatin 20mg, in the presence of telmisartan/amlodipine, rosuvastatin Cmax increased approximately 2.1-fold and AUC increased approximately 1.2-fold. Therefore, when administering this medication, the potential risk due to the increase in rosuvastatin Cmax should be assessed, and the patient should be monitored closely.

Ingredients

Manufacturer
Jeil Pharmaceutical Co., Ltd.

Efficacy & effects

Treatment of hypertension and dyslipidemia, and inhibition of atherosclerosis progression and cardiovascular risk

  • Essential hypertension
  • primary hypercholesterolemia
  • heterozygous familial hypercholesterolemia
  • mixed hyperlipidemia
  • homozygous familial hypercholesterolemia
  • hypercholesterolemia
  • primary dysbetalipoproteinemia
  • elevated high-sensitivity C-reactive protein
  • hypertension
  • low HDL cholesterol
  • smoking
  • family history of early coronary artery disease
View approved original text

This medication is used in patients with essential hypertension whose blood pressure is not well controlled with monotherapy of telmisartan and amlodipine when atorvastatin needs to be administered concurrently. The telmisartan/amlodipine combination is effective in controlling blood pressure, and atorvastatin helps improve dyslipidemia such as hypercholesterolemia. Especially, when not controlled by diet and exercise, atorvastatin lowers cholesterol levels and delays the progression of atherosclerosis. It is also used to reduce the risks of stroke, myocardial infarction, and vascular reintervention in patients at high cardiovascular risk. Therefore, this drug helps manage cardiovascular health effectively by targeting improvements in both blood pressure and blood lipids simultaneously.

How to take

Adult dose

Take 1 tablet once daily with water, regardless of meals. If possible, it is recommended to take it at the same time each day (e.g., in the morning). This medication is for adults only. The dose should be individualized for each patient based on the efficacy and tolerability of the telmisartan/amlodipine combination and rosuvastatin. For patients taking the telmisartan/amlodipine combination together with rosuvastatin alone, they may switch to this medication (a combination product containing the same amount of each active ingredient) for convenience. ○ Telmisartan/amlodipine combination Before administering the telmisartan/amlodipine combination, it is recommended that the dose be adjusted using the individual components (amlodipine or telmisartan). However, if blood pressure is not controlled with the individual components, switching directly to the telmisartan/amlodipine combination may be considered as follows. - 40/5 mg: For patients whose blood pressure is not adequately controlled with amlodipine 5 mg or telmisartan 40 mg. - 80/5 mg: For patients whose blood pressure is not adequately controlled with amlodipine 5 mg or this medication 40/5 mg. - 40/10 mg: For patients whose blood pressure is not adequately controlled with amlodipine 10 mg. - 80/10 mg: For patients whose blood pressure is not adequately controlled with amlodipine 10 mg or this medication 40/10 mg. ◦ Patients with renal impairment: No dose adjustment is necessary in patients with mild or moderate renal impairment. However, in patients with severe renal impairment, it is recommended to start treatment at a low dose and increase the dose gradually. Periodic monitoring of serum potassium and creatinine levels is also recommended. ◦ Patients with hepatic impairment: The daily dose of telmisartan should not exceed 40 mg in patients with mild or moderate hepatic impairment. ◦ Elderly patients: In elderly patients aged 75 years or older, treatment should be started at a low dose and the dose increased gradually because amlodipine clearance is reduced. ○ Rosuvastatin 1. Primary hypercholesterolemia (type IIa, including heterozygous familial hypercholesterolemia), mixed dyslipidemia (type IIb), primary dysbetalipoproteinemia (type III), and homozygous familial hypercholesterolemia Patients should follow a standard cholesterol-lowering diet before and during treatment with rosuvastatin and continue it throughout the treatment period. Rosuvastatin may be taken at any time of day, regardless of meals. The initial dose is 5 mg once daily. If a greater reduction in LDL cholesterol is needed, the dose may be adjusted to a maintenance dose. The maintenance dose is 10 mg once daily, which controls the condition in most patients. The maintenance dose should be adjusted as appropriate according to LDL cholesterol levels, treatment goals, and the patient's response, at intervals of 4 weeks or longer; the dose may be increased to a maximum of 20 mg once daily. 2. Elderly patients: No dose adjustment is necessary. 3. Patients with renal impairment: No dose adjustment is necessary in patients with mild or moderate renal impairment. Do not administer to patients with severe renal impairment. Particular caution should be exercised when administering rosuvastatin 20mg to patients with moderate renal impairment. 4. Patients with hepatic impairment: No increase in systemic exposure to rosuvastatin was observed in patients with a Child-Pugh score of 7 or less, but an increase was observed in patients with a Child-Pugh score of 8 or 9. Renal function testing should be considered in these patients. There is no experience with administration in patients with a Child-Pugh score greater than 9. Do not administer rosuvastatin to patients with active liver disease. 5. Race: Because systemic exposure to rosuvastatin is increased in Asian patients, the recommended initial dose is 5 mg. Administration of the 40 mg dose is contraindicated. 6. Patients predisposed to myopathy: The recommended initial dose for patients predisposed to myopathy is 5 mg. Administration of the 40 mg dose of rosuvastatin is contraindicated in some of these patients. In a drug interaction study of the active ingredients of this medication, telmisartan/amlodipine 80/10mg and rosuvastatin 20mg, in the presence of telmisartan/amlodipine, rosuvastatin Cmax increased approximately 2.1-fold and AUC increased approximately 1.2-fold. Therefore, when administering this medication, the potential risk due to the increase in rosuvastatin Cmax should be assessed, and the patient should be monitored closely.

Precautions

This medication can cause serious harm to the fetus during pregnancy, so it should be discontinued immediately upon confirmation of pregnancy. Patients with allergies to any of the ingredients or certain diseases should not use this product. For example, patients with severe liver impairment, kidney impairment, history of angioedema, or severe aortic stenosis may be at risk when taking this medication. Caution is especially needed in patients with hypotension, hyperkalemia, liver impairment, and kidney impairment, and elderly patients should use this with care. During treatment, symptoms such as muscle pain, muscle weakness, and muscle cramps may occur, so if these symptoms arise, consultation with a doctor is necessary. Additionally, regular monitoring is required due to possible liver and kidney function abnormalities. This medication may interact with other drugs, so it is important to inform the doctor or pharmacist about any other medications being taken. Women of childbearing potential should use appropriate contraception while taking this medication, and breastfeeding should be avoided or breastfeeding should be suspended during treatment. It is not recommended for children or adolescents as safety and efficacy have not been established. In case of overdose, symptoms such as hypotension, dizziness, and cardiac arrhythmias may occur, and immediate medical attention is required. This medication should be kept out of the reach of children, and it is advisable not to transfer it to another container.

Side effects

Peripheral edema, dyspepsia, frequent bowel movements, diabetes mellitus, dizziness, xerotic vesicles, hives, unstable angina, onychomycosis, lumbar spinal stenosis, otorrhea, vertigo, chronic gastritis, hiatal hernia, skeletal muscle pain, dysuria, rhinitis, discomfort in the oropharynx, pulmonary disease, unspecified intestinal disease, benign gastrointestinal neoplasm, hemorrhoids, skeletal pain, osteoporosis, sensory loss, movement disorders, atherosclerosis, frequent urination, tinnitus, hearing loss, bad breath, fatty liver, upper respiratory infection, low back pain, sinusitis, diarrhea, pharyngitis, flu-like symptoms, dyspepsia, myalgia, urinary tract infection, abdominal pain, headache, dizziness, pain, fatigue, cough, hypertension, chest pain, nausea, erectile dysfunction, erectile dysfunction, autonomic nervous system disorders, fever, leg pain, lassitude, palpitations, dependent edema, angina, rapid pulse, leg edema, abnormal ECG, insomnia, drowsiness, migraine, sensory disturbance, involuntary muscle contractions, sensory loss, flatulence, constipation, gastritis, vomiting, dry mouth, hemorrhoids, gastroenteritis, enteritis, gastroesophageal reflux, toothache, nonspecific gastrointestinal disorders, gout, hypercholesterolemia, anxiety, depression, irritability, infection, fungal infection, abscess, otitis media, asthma, bronchitis, rhinitis, shortness of breath, epistaxis, dermatitis, rash, eczema, pruritus, angioedema, polymorphic erythema, erythematous rash, papular erythema, visual disturbances, conjunctivitis, diplopia, ocular pain, ear pain, frequent urination, urinary disorders, nocturia, dry mouth, increased sweating, hyperglycemia, thirst, leukopenia, purpura, thrombocytopenia, headache, dizziness, constipation, nausea, abdominal pain, pruritus, rash, hives, myalgia, myopathy, rhabdomyolysis, asthenia, angioedema, thrombocytopenia, jaundice, hepatitis, Stevens-Johnson syndrome, drug reaction with eosinophilia and systemic symptoms, lupus-like syndrome, muscle rupture, immune-mediated necrotizing myopathy, hematuria, edema, depression, sleep disorders, interstitial lung disease, sexual dysfunction, gynecomastia, fatal and non-fatal liver failure, cognitive decline, forgetfulness, amnesia, memory impairment, confusion, hypotension, tachycardia, bradycardia, acute renal failure, severe hypotension, reflex tachycardia, shock, non-cardiogenic pulmonary edema, acute renal failure, thrombocytopenia, increased serum creatinine

Not everyone experiences these, and they can vary from person to person.

Storage

This medication is sensitive to light, so it should be stored in a container that does not allow light in. Additionally, to keep the medication safe, it is recommended to store it at room temperature between 1 degree and 30 degrees Celsius.

Appearance and packaging

Appearance

An oval bilayer tablet consisting of a white layer and a light blue layer

Package unit

30 tablets (10 tablets/PTP x 3)

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.